Naftidrofuryl
From Wikipedia, the free encyclopedia
 |
|
|
Naftidrofuryl
|
|
| Systematic (IUPAC) name | |
| 2-diethylaminoethyl 2-(naphthalen-1-ylmethyl)- 3-(oxolan-2-yl)propanoate |
|
| Identifiers | |
| CAS number | |
| ATC code | C04 |
| PubChem | |
| Chemical data | |
| Formula | C24H33NO3 |
| Mol. mass | 383.524 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Naftidrofuryl (INN, also known as nafronyl or as the oxalate salt nafronyl oxalate) is a drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic.[1] It may also be a 5-HT2 receptor antagonist.
[edit] References
- ^ Reynolds, J.E.F. (ed.) (1993). Martindale: The extra pharmacopoeia, 30th edition, London: Pharmaceutical Press, p. 1310. ISBN 0853693005.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
